11/15
08:04 am
inkt
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
11/15
08:03 am
inkt
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target lowered by analysts at Robert W. Baird from $8.00 to $4.00. They now have an "outperform" rating on the stock.
Low
Report
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target lowered by analysts at Robert W. Baird from $8.00 to $4.00. They now have an "outperform" rating on the stock.
11/15
02:22 am
inkt
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Low
Report
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
11/14
07:09 am
inkt
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update [Yahoo! Finance]
Medium
Report
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update [Yahoo! Finance]
11/14
07:00 am
inkt
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
Medium
Report
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
11/11
07:30 am
inkt
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
Low
Report
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
11/7
10:00 am
inkt
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
Medium
Report
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
10/31
09:15 am
inkt
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
Low
Report
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
10/9
08:33 am
inkt
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
10/8
07:43 am
inkt
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors [Yahoo! Finance]
High
Report
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors [Yahoo! Finance]
10/8
07:30 am
inkt
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
Medium
Report
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
10/4
09:15 am
inkt
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024 [Yahoo! Finance]
Medium
Report
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024 [Yahoo! Finance]
10/4
09:10 am
inkt
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
Medium
Report
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
9/3
07:30 am
inkt
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
Low
Report
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference